QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NYSE:AMAM

Ambrx Biopharma - AMAM Stock Forecast, Price & News

$1.85
-0.03 (-1.60%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.77
$1.92
50-Day Range
$0.41
$4.54
52-Week Range
$0.38
$5.12
Volume
278,240 shs
Average Volume
720,049 shs
Market Capitalization
$71.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Ambrx Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
116.2% Upside
$4.00 Price Target
Short Interest
Healthy
1.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.24) to ($0.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

598th out of 1,030 stocks

Biological Products, Except Diagnostic Industry

92nd out of 169 stocks


AMAM stock logo

About Ambrx Biopharma (NYSE:AMAM) Stock

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AMAM Stock News Headlines

Ambrx Biopharma: Some Promise, Much Uncertainty
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Cowen & Co. Keeps Their Buy Rating on Ambrx Biopharma (AMAM)
Meet the Biotech Stock That Jumped Over 1000% in One Day
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Ambrx Biopharma to Host Corporate Update Conference Call
Ambrx Biopharma Inc. ADR
See More Headlines
Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AMAM Company Calendar

Today
2/02/2023
Next Earnings (Estimated)
4/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+116.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.45 million
Book Value
$4.92 per share

Miscellaneous

Free Float
36,648,000
Market Cap
$71.45 million
Optionable
Not Optionable
Beta
-2.17

Key Executives

  • Ms. Sonja Nelson CPA (Age 49)
    Chief Financial & Operating Officer
  • Mr. Daniel J. O'Connor J.D. (Age 57)
    CEO, Pres & Director
  • Dr. Ying J. Buechler Ph.D.
    Chief Technology Officer
  • Dr. Shawn Shao-Hui Zhang Ph.D.
    Chief Scientific Officer













AMAM Stock - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMAM shares.
View AMAM analyst ratings
or view top-rated stocks.

What is Ambrx Biopharma's stock price forecast for 2023?

2 brokers have issued 1-year price targets for Ambrx Biopharma's stock. Their AMAM share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 112.8% from the stock's current price.
View analysts price targets for AMAM
or view top-rated stocks among Wall Street analysts.

How have AMAM shares performed in 2023?

Ambrx Biopharma's stock was trading at $2.27 on January 1st, 2023. Since then, AMAM shares have decreased by 17.2% and is now trading at $1.88.
View the best growth stocks for 2023 here
.

Are investors shorting Ambrx Biopharma?

Ambrx Biopharma saw a decrease in short interest in the month of December. As of December 30th, there was short interest totaling 965,700 shares, a decrease of 48.6% from the December 15th total of 1,880,000 shares. Based on an average trading volume of 3,470,000 shares, the short-interest ratio is presently 0.3 days. Currently, 2.6% of the shares of the stock are sold short.
View Ambrx Biopharma's Short Interest
.

When is Ambrx Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our AMAM earnings forecast
.

When did Ambrx Biopharma IPO?

(AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO.

What is Ambrx Biopharma's stock symbol?

Ambrx Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMAM."

Who are Ambrx Biopharma's major shareholders?

Ambrx Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Ambrx Biopharma?

Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ambrx Biopharma's stock price today?

One share of AMAM stock can currently be purchased for approximately $1.88.

How much money does Ambrx Biopharma make?

Ambrx Biopharma (NYSE:AMAM) has a market capitalization of $72.61 million and generates $7.45 million in revenue each year.

How can I contact Ambrx Biopharma?

The official website for the company is ambrx.com. The company can be reached via phone at 858-875-2400.

This page (NYSE:AMAM) was last updated on 2/2/2023 by MarketBeat.com Staff